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Sofosbuvir displays a high phenotypic barrier to resistance, and it is a component of several combination therapies for hepatitis
C virus (HCV) infections. HCV fitness can be a determinant of decreased sensitivity to direct-acting antiviral agents such as tel-
aprevir or daclatasvir, but fitness-dependent decreased drug sensitivity has not been established for drugs with a high pheno-
typic barrier to resistance. Low- and high-fitness HCV populations and biological clones derived from themwere used to infect
Huh-7.5 hepatoma cells. Sofosbuvir efficacy was analyzed by measuring virus progeny production during several passages and
by selection of possible sofosbuvir resistance mutations determined by sequencing the NS5B-coding region of the resulting pop-
ulations. Sofosbuvir exhibited reduced efficacy against high-fitness HCV populations, without the acquisition of sofosbuvir-
specific resistance mutations. A reduced sofosbuvir efficacy, similar to that observed with the parental populations, was seen for
high-fitness individual biological clones. In independently derived high-fitness HCV populations or clones passaged in the pres-
ence of sofosbuvir, M289L was selected as the only substitution in the viral polymerase NS5B. In no case was the sofosbuvir-spe-
cific resistance substitution S282T observed. High HCV fitness can lead to decreased sensitivity to sofosbuvir, without the acqui-
sition of specific sofosbuvir resistance mutations. Thus, fitness-dependent drug sensitivity can operate with HCV inhibitors that
display a high barrier to resistance. This mechanismmay underlie treatment failures not associated with selection of sofosbuvir-
specific resistance mutations, linked to in vivo fitness of pretreatment viral populations.
Hepatitis C virus (HCV) infection affects about 2.3% of theworld population, with treatment and patient management
costs being an important burden for health systems (1). Treat-
ment efficacy, quantified as the rate of sustained viral response,
has improvedmarkedly with the introduction of direct-acting an-
tiviral agents (DAAs) (2). DAAs include inhibitors of the viral
protease NS3-4A (telaprevir [TPV], boceprevir, simeprevir, pari-
taprevir/ritonavir, asunaprevir, etc.), of nonstructural protein
NS5A (daclatasvir [DCV], ledipasvir, ombitasvir, etc.), and the
polymerase NS5B (nonnucleoside analogues, such as dasabuvir,
and one nucleoside analogue, such as sofosbuvir [SOF]). Many
DAAs have been licensed for human use, and others are still in
preclinical and clinical assessment.
A major issue in antiviral treatments is the selection of inhibi-
tor-resistant mutants leading to treatment failure. Selection is in-
fluenced by genetic and phenotypic barriers to resistance. The
genetic barrier depends on the number and type of mutations
needed for the RNA to encode amino acid substitutions needed to
confer resistance. The phenotypic barrier is determined by the
fitness cost inflicted upon the virus by the mutations associated
with resistance. Barriers vary depending on the nature of the an-
tiviral agent, the viral genomic nucleotide sequence, and popula-
tion parameters. For statistical reasons a large, replicating viral
population increases the likelihood that required mutations will
occur with genomes harboring fitness-restoring compensatory
mutations (reviewed in reference 3). In the case of HCV, inhibi-
tors of NS3-4A and NS5A and nonnucleoside inhibitors of NS5B
generally exhibit a low phenotypic barrier to resistance while nu-
cleoside analogues display a high barrier (4–8).
Recent results suggest that HCV fitness may be a determinant
of decreased sensitivity to antiviral agents (9). Passage of the pa-
rental populationHCV (passage 0, p0) [based on the JFH-1-based
chimera Jc1FLAG2(p7-nsGluc2A)] in Huh-7.5 reporter cells re-
sulted in increased fitness, as expected from continued virus rep-
lication in the same environment (3). Fitness levels of the popu-
lations at passage 45 (HCV p45) and at passage 100 (HCV p100)
were 1.9 0.3 and 2.2 0.4, respectively, relative to the fitness of
HCV p0 (fitness 1). These fitness increases were accompanied by
an expansion of the mutant spectrum, with a minimummutation
frequency increase of 1.7-fold and 2.6-fold forHCVp45 andHCV
p100, respectively, relative to HCV p0 (9). The passaged popula-
tions exhibited decreased sensitivity to the anti-HCV inhibitors
TPV, DCV, cyclosporine (CsA), ribavirin (RBV), and alpha inter-
feron (IFN-) (9, 10). In no case was resistance associated with
specific mutations in the viral genome. Further proof was pro-
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vided by parallel kinetics of progeny production over a 1,000-fold
range of multiplicities of infection (MOIs) in the presence of the
drugs and bymaintenance of the resistance phenotypes in biolog-
ical clones isolated from the passagedHCVpopulations (9). It was
concluded that fitness or a fitness-associated trait was a drug re-
sistance determinant for HCV (9, 11, 12).
This prior study did not examine a DAA with a high pheno-
typic resistance barrier such as SOF, the prodrug of-D-2=-deoxy-
2=--fluoro-2=--C-methyluridine, which, in its triphosphate
form, acts as chain terminator during HCV RNA elongation (13,
14). SOF has been used in monotherapy and in various combina-
tions with ribavirin and other DAAs (ledipasvir, simeprevir, etc.)
with average sustained virological response (SVR) rates exceeding
90% (see, for example, references 15 to 20, among others). Muta-
tions associated with SOF resistance have been described previ-
ously. Substitution S282T in NS5B, which confers resistance to
2=-C-methylated nucleotide analogues, was first described in rep-
licon assays (21) and subsequently selected in vitro using HCV
replicons of genotypes 1 to 6 (22). For genotype 1a, S282T was
found in combination with I434M. For genotype 2a, substitution
T179A,M289L, or I293L was required for resistance together with
S282T, while substitutions M343T and H479P increased the rep-
lication capacity of replicons carrying S282T (23). Regarding SOF
resistance in vivo, NS5B S282Thas been found in a patient infected
with HCV genotype 2b who relapsed after SOF monotherapy in a
phase 2 trial (17). In another study, 99.8% of the viral population
harbored the S282T substitution after 4 weeks of SOF mono-
therapy, despite the low frequency of the mutant at baseline (24).
S282T was also found in one subject who relapsed 4 weeks after
SOFmonotherapy (25) and in twopatients infectedwith genotype
1 who did not achieve a sustained virological response after treat-
ment with SOF/RBV (26) or SOF/ledipasvir (19). Recently, sub-
stitutions S282G/C/R were detected in nine patients, and in silico
models suggest that these substitutions may be associated with
SOF resistance (27). Amutant with a L159F/L320F double substi-
tution emerged in one genotype 1b-infected patient, and the virus
showed reduced susceptibility to SOF andmericitabine in cell cul-
ture (28). HCV genotype 3 with NS5B substitutions L159F and
V321A were isolated from patients in phase 3 clinical trials with
SOF-based regimens, but these substitutions did not affect overall
susceptibility to SOF; in other patients that presented partial re-
sponses or relapse to SOF treatment, NS5B substitutions found
included L159F, C316N, S282R, and/or L320F, but their clinical
significance has not been established (reviewed in reference 29).
Structural bioinformatics analyses fromnext-generation sequenc-
ing (NGS) data of virus frompatients participating in clinical trials
with SOF confirmed that substitutions L159F, V321A, C316N,
and S282R were associated with treatment failure (7). Thus, de-
spite a generally accepted high phenotypic barrier to achieve SOF
resistance, both in vitro assays and clinical results suggest that a
number of substitutions in NS5B—which differ depending on the
viral genotype—can confer diminished susceptibility to this in-
hibitor, with S282T playing a key role (30).
Given the remarkable clinical impact of SOF-basedHCV treat-
ments, it was of interest to investigate if passaged, high-fitness
HCV populations displayed decreased sensitivity to SOF in the
absence of SOF-specific resistance mutations. In the present re-
port we show that this is indeed the case, suggesting that inherent
pretreatment fitness of HCV can alter sensitivity to sofosbuvir-
based regimens, without the need for selection of specific resis-
tance mutants.
MATERIALS AND METHODS
Cells, viruses, infections, and titration of infectivity. The origin of the
Huh-7 Lunet, Huh-7.5, and Huh-7.5 reporter cell lines, conditions for
their growth, preparation of HCV, and titration of infectivity have been
described previously (9, 10, 31–33). Huh-7 Lunet cells were used for elec-
troporation of RNA transcribed from plasmid Jc1FLAG2(p7-nsGluc2A)
(genotype 2a) or its GNN replication-defective mutant used as a negative
control (10). Supernatants of the passaged electroporated cells were
pooled, the virus was concentrated 20-fold, and the concentrate was used
to infect Huh-7.5 reporter cells to prepare the parental virus HCV p0;
further details are described in Perales et al. (10). HCVp0was subjected to
100 serial passages in Huh-7.5 reporter cells. For the first passage, 4 105
Huh-7.5 reporter cells were infected with HCV p0 at a multiplicity of
infection (MOI) of 0.5 50% tissue culture infective doses (TCID50)/cell.
For subsequent passages, the same numbers of cells were infected with the
virus contained in 0.5 ml of cell culture supernatant from the previous
infection; at passage 60 the volume of supernatant used for infection was
diluted gradually up to 20-fold to limit cytopathology. The MOIs at dif-
ferent passages ranged from 0.2 to 5 TCID50/cell. Passage (p) numbers are
identified as follow: HCV p45 and HCV p100 are the HCV p0 population
subjected to 45 and 100 serial passages, respectively, in Huh-7.5 reporter
cells.
To titrate HCV infectivity, viral samples were serially diluted and
added to Huh-7.5 cells seeded 15 h earlier in 96-well plates (6,400 cells/
well). At 3 days postinfection, the cells were washed with phosphate-
buffered saline (PBS), fixed with cold methanol, and stained with anti-
NS5A monoclonal antibody 9E10 (10, 33).
Sofosbuvir treatment.Astock solution of 10mMSOF (SelleckChem-
icals) was prepared in dimethyl sulfoxide (DMSO) and stored at80°C.
Prior to use, the solution was diluted in Dulbecco’s modified Eagle’s me-
dium (DMEM) to reach the desired concentration. SOF toxicity (the SOF
concentration needed to kill 50% of the cells, or cytotoxic concentration
50 [CC50]), and inhibitory activity (the SOF concentration needed to
inhibit the infectious progeny production by 50% [IC50]) were measured
as previously described (9).
Preparation of biological clones fromhepatitis C virus populations.
HCV p0, HCV p45, and HCV p100 were treated with mild detergent
(sodiumdeoxycholate at 0.01%) for 10min at room temperature, diluted,
and applied to Huh-7.5 cell monolayers in M96 wells. The cell culture
supernatant of a well with a single cluster of Huh-7.5-infected cells was
used to infect 1  105 Huh-7.5 cells in an M24 well, followed by an
infection of 4 105 Huh-7.5 cells in anM6 dish. Finally, 1 106 Huh-7.5
cells were infected in a p60 dish under standard infection conditions (9).
RNA extraction, cDNA synthesis, PCR amplification, and nucleo-
tide sequencing. Intracellular viral RNAwas extracted from infected cells
at each passage using aQiagenRNeasy kit (Qiagen, Valencia, CA), accord-
ing to themanufacturer’s instructions. HCVRNAwas reverse transcribed
using avian myeloblastosis (AMV) reverse transcriptase (Promega), and
the PCR amplification of the NS5B-coding region was carried out using
AccuScript (Agilent Technologies) with oligonucleotide primers Jc1-
NS5B-F1, 5=-TGGTCTACTTGCTCCGAGGAGG (sense orientation; the
5= nucleotide corresponds to genomic residue 7625), and Jc1-NS5B-R4,
5=-AGTTAGCTATGGAGTGTACCTAG (antisense orientation; the 5=
nucleotide corresponds to genomic residue 9476; residue numbering is
that of HCV strain JFH-1). Amplification products were analyzed by aga-
rose gel electrophoresis, using HindIII-digested 29 DNA as a molecular
mass standard. Amplification controls in the absence of RNA were run in
parallel to ascertain the absence of contamination by undesired templates.
Nucleotide sequences were determined on the two strands of the am-
plified DNA according to standard procedures (10, 34).
Statistical analyses. To determine the statistical significance of dif-
ferences in serial-passage experiments, two-way analysis of variance
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(ANOVA) was performed with the SPSS, version 13.0, statistical pack-
age (SPSS, Inc.).
RESULTS
Dose-dependent inhibition of HCV by sofosbuvir in cell cul-
ture. To quantify the toxicity of SOF for Huh-7.5 reporter cells
and its inhibitory activity on progeny production by the parental
HCV p0 population, CC50 and IC50s were obtained (Fig. 1A and
B). The IC50 (20 3 nM) was at least 2,000-fold higher than the
CC50 (50 	M), yielding a therapeutic index (TI), defined as
CC50/IC50, of 2,000. The TI value allowed exploration of the
inhibitory effect over a 12-fold range of SOF concentrations in the
course of three serial passages of HCV p0 (Fig. 1C). The results
indicate a dose-dependent inhibition ofHCVp0 progeny produc-
tion under conditions of undetectable toxicity for the host Huh-
7.5 reporter cells.
Resistance to sofosbuvir of multiply passaged HCV p0. To
test if passaged HCV displayed resistance to SOF, HCV p0, HCV
p45, and HCV p100 were subjected to 10 serial infections in the
absence or presence of SOF (800 nMand 1,200 nM) (Fig. 2). In the
absence of SOF,HCVp100 showed increased progeny production
during the first five passages comparedwith result withHCVp0 or
HCV p45, indicative of its high fitness (9). Passage in the presence
of 800 nM SOF resulted in loss of infectivity of HCV p0 by passage
4 but survival of HCV p45 and HCV p100, with at least a 103-fold
higher progeny production than that of HCV p0 (the difference of
progeny production betweenHCVp45 orHCVp100 andHCVp0
was statistically significant [P
 0.001; ANOVA test], but the dif-
ference between results with HCV p45 and HCV p100 was not
statistically significant [P 0.05; ANOVA test]). In the presence
of 1,200 nM SOF, the three populations were inhibited; but while
the infectivity of HCV p0 was not detectable by passage 2, HCV
p100 survived at least during five passages, and HCV p45 in-
creased its viral production from passages 8 to 10 (Fig. 2) (the
difference in progeny production between HCV p45 and HCV
p0 or HCV p100 was statistically significant [P 
 0.001;
ANOVA test], but the difference between HCV p0 and HCV
p100 was not significant [P 0.05; ANOVA test]). Thus, HCV
passaged in cell culture in the absence of SOF exhibited signif-
icant resistance to SOF.
Mutations in the NS5B-coding regions of high-fitness HCV
populations passaged in the absence or presence of sofosbuvir.
The consensus sequence of the NS5B-coding region of HCV p0,
HCV p45, and HCV p100 did not reveal detectable substitutions
previously associated with SOF resistance, except for T179A pres-
ent in 50% of genomes in HCV p100 (Fig. 3). T179A has not
been considered a SOF resistance substitution per se in the absence
of S282T.When tested as a single replacement, T179A remained at
low frequency levels at passage 5 in the presence of 800 nM SOF
and was undetectable by passage 10. Instead, M289L was domi-
nant at passage 10 (Fig. 3). When HCV p100 was subjected to five
FIG1 Inhibition of hepatitis C virus by sofosbuvir. (A)Determination of 50%
cytotoxic concentration (CC50). Huh-7.5 reporter cells (1.3 10
4) were incu-
bated with the indicated concentration of sofosbuvir (SOF) during 72 h
at 37°C, and the numbers of viable cells were counted using MTT [3-(4,
5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide], as described pre-
viously (9). (B) Determination of the drug concentration required for 50%
inhibition (IC50) of infectious HCV yield. Huh-7.5 reporter cells (1.0  10
5)
were infected with 3 103 TCID50 of HCV p0 in the presence of the indicated
concentrations of SOF. Virus titers were determined in the cell culture super-
natants at 72 h postinfection. Viral titers are given as the percentages of the
titers obtained in the infection in the absence of SOF. (C) Progeny production
in the course of three serial passages of HCV p0 in the presence of increasing
concentrations of SOF, as indicated. Infection conditions are those explained
in the description of panel B. Procedures are detailed in Materials and Meth-
ods.
FIG 2 Infectious progeny production of hepatitis C virus populations pas-
saged in the absence or presence of sofosbuvir. HCV p0, HCV p45, and HCV
p100 were subjected to 10 serial passages in the absence (no drug) or the
presence of 800 nM or 1,200 nM sofosbuvir (SOF). For the first passage, 4
105Huh-7.5 reporter cells were infectedwith 1.2 104TCID50 of the indicated
virus, to give amultiplicity of infection (MOI) of 0.03 TCID50/cell. For succes-
sive infections, 4  105 Huh-7.5 reporter cells were infected with the virus
contained in 500	l of the cell culture supernatant from the previous infection,
yielding a range of MOIs of 1.25 105 to 3.95 TCID50/cell. Infections were
allowed to proceed for 72 h. The abscissa axes indicate the limits of detection of
virus titers. Infection conditions are further detailed inMaterials andMethods.
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passages in the presence of 1,200 nM SOF, T179A was dominant,
and M289L was present in about 25% of the genomes; this viral
population did not survive beyond passage 5 (Fig. 2). M289L also
became dominant upon passage of HCV p45 in the presence of
800 nM or 1,200 nM SOF (Fig. 3). Selection of this substitution
raised the possibility that the SOF resistance ofHCVp45 andHCV
p100was due to the presence of genomeswith thismutation at low
frequency even though it was not detected in the population con-
sensus sequences. To address this, SOF resistance was examined
using biological viral clones isolated from the HCV p0, HCV p45,
and HCV p100 populations.
Passage of biological clones of hepatitis C virus in the ab-
sence or presence of sofosbuvir. Three biological clones from
each of the HCV p0, HCV p45, and HCV p100 populations were
isolated by endpoint virus dilution and successive infections, as
detailed in Materials and Methods. Critical to interpreting subse-
quent results is that the number of rounds of amplification under-
gone by the individual clones to obtain the working stocks was at
least 3-fold lower than the number of rounds involved in the prep-
aration of HCV p0 from the initial plasmid transcript (9). A low
number of replication rounds ensures a mutant spectrum diver-
sification lower than that of the reference HCV p0 population.
Each of the nine biological clones was subjected to three pas-
sages in the absence or presence of 800 nMSOF.Despite variations
among individual clones from the same population, the average
progeny production at passage 3 by the HCV p45 and HCV p100
clones was 8.5-fold and 100.9-fold, respectively, higher than the
average production by the HCV p0 clones (P 0.7 and P 0.02,
respectively; ANOVA test) (Fig. 4). Since minority HCV genomes
harboring a SOF resistance mutation should have been excluded
by the cloning process, this result suggests that viral fitness or a
fitness-related trait can confer SOF resistance to HCVwithout the
presence of specific SOF resistance mutations. This differential
sensitivity to SOF did not vary over the 630,000-fold range ofMOI
values involved in the passages (Fig. 4).
Evidence of a dual fitness-dependent mechanism of drug re-
sistance. To investigate the possible selection of SOF resistance
mutations during passage of biological clones in the presence of
SOF, the NS5B-coding regions of clones passaged in the absence
or presence of SOF that yielded sufficient viral RNA were se-
quenced. The results indicate that in some (but not all) popula-
tions, mutations leading to an amino acid substitution previously
related to SOF resistance were selected, reaching partial or com-
plete dominance (Fig. 5). The most significant substitutions were
T179A andM289L, for opposite reasons. In our experimental sys-
tem T179A can be excluded as a bona fide SOF resistance muta-
tion because it occurred only in a biological clone from HCV p0
in the absence and presence of SOF. M289L became partially or
totally dominant in two out of the six clones tested and always in
the presence of SOF. In no case was the SOF resistance substitu-
tion S282T selected (Fig. 5). In conclusion, highHCV basal fitness
is a factor of diminished sensitivity to SOF and a parameter that
can promote selection of specific mutations related to SOF resis-
tance.
DISCUSSION
In this report we have documented a fitness-dependent resistance
to the high-barrier anti-HCV DAA SOF. This drug was chosen
because of its importance in current HCV therapies (e.g., refer-
ences 15 to 20 and 35 to 40). The results show that HCV p45 and
HCVp100 are significantlymore resistant thanHCVp0 to SOF. A
comparison with the previous results with other inhibitors shows
quantitative differences. While the inhibition by IFN-, ribavirin,
TPV, DCV, and CsA was 513-, 412-, 453-, 13,658-, and 309-fold,
respectively, greater for HCV p0 than HCV p100, for SOF this
differencewas only 34-fold (compare Fig. 2with Fig. 3 in reference
9). For this comparison, the drug concentrations usedwere 6.0- to
50-fold higher than the corresponding IC50s, and titers were mea-
sured at passage 3 in infections carried out at an MOI of 0.03
TCID50/cell. Additional work is needed to determine if the lower
difference observedwith SOF thanwith the otherDAAsmay relate
to its higher resistance barrier.
In a study with HCV genotype 2a replicons, Lam and col-
leagues observed that themajor SOF resistance substitution S282T
was selected onlywhen replicon carrier cells were treatedwith SOF
concentrations that were 70-fold higher than the IC50 (23). Since
the SOF concentrations used in our HCV inhibition experiments
were 32- to 48-fold higher than the IC50, it is not unexpected that
S282T was not selected in any of the populations or biological
clones passaged in the presence of SOF.
The molecular basis and the possible clinical impact of the
basal HCV fitness level on treatment response are unknown. Both
in the cell culture system and among clinical samples of HCV,
mutations that alter HCV fitness have been described (10, 41). As
a possible mechanism, we proposed a competition between the
number of replicating genomes at each replicative unit in an in-
FIG 3 Amino acid substitutions in the consensus sequence of the NS5B (poly-
merase)-coding region of the hepatitis C virus passaged in the absence or
presence of sofosbuvir. Viral populations and sofosbuvir (SOF) concentra-
tions (nanomolar) are indicated in the filled boxes on the left; the virus passage
number (p) is given in the last column. The upper row indicates the amino
acids where substitutions have been found and their positions in the NS5B
protein. The boxed amino acids in the second row are those that have been
related to SOF resistance in HCV genotype 2a, with the major resistance sub-
stitution S282T highlighted. The two panels below the sequence describe the
amino acid substitutions in each population, with those that have been related
to SOF resistance boxed. A slash between two unmarked amino acids indicates
that both were present at about 50% frequency in the consensus sequence,
according to the peaks in the sequencing data; a slash with an asterisk indicates
dominance (around 70% frequency) of the first amino acid in the pair. The
complete repertoire of synonymous and nonsynonymous mutations found in
the viral populations is listed in Table S1 in the supplemental material. Proce-
dures for nucleotide sequencing are described in Materials and Methods.
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fected cell and the concentration of inhibitor that reaches the rep-
licative units (9). This model is plausible if viral fitness is essen-
tially due to increased intracellular viral replication. The other
model is an increased stability of the replication complex, with
longer time for the functional HCV RNA to decay away in the
absence of replication. Experiments to test these possibilities are in
progress. Regarding the possible clinical significance of our find-
ings, the main difficulty is to estimate the basal HCV fitness at the
onset of the treatment. Theoretical studies have inferred fitness
landscapes from sequence data, but the majority of them have
ignored intrahost heterogeneity and have regarded viruses as
“strains” rather than mutant clouds. An interesting approach has
been taken by N. Beerenwinkel and colleagues to infer fitness
landscapes from deep-sequencing data (42, 43). They likened
HIV-1 fitness parameters to the mutant spectrum composition
using quasispecies theorywith a number of assumptions to permit
the computation (mutation-selection equilibrium, use of a lim-
ited haplotype subset, uniform mutation rate, etc.). Use of these
computational tools together with clinical data that may be asso-
ciated with highHCVfitness (duration of the infection, viral load,
and mutant spectrum complexity) (44, 45) may provide a predic-
tive tool for inhibitor resistance independent of specific muta-
tions, and such efforts are in progress.
It has been observed that treatment failures are more frequent
in patients that have remained infected for a long time, and it has
been well established that prolonged infections in the same envi-
ronment result in a fitness gain (reviewed in reference 3). There is
recent evidence of patients that do not respond to treatment in
whom resistance mutations are not detected after HCV rebound.
In a cohort of 1,797 patients subjected to TPVmonotherapy, 28%
were nonresponders, and the virus in 23% did not include detect-
able TPV resistance mutations (46). In a large cohort of 1,662
patients treated with SOF either alone or in combination with
ribavirin or ribavirin and pegylated IFN-, 18% of patients did
not attain an SVR; in many cases treatment failure could not be
attributed to specific resistance mutations (25). The authors pro-
posed that residual HCV replication might occur in the liver dur-
ing drug treatment, with undetectable RNA in the blood. Other
modeling studies have shown that low-level virus replication may
occur in the presence of inhibitor, without the selection of drug-
resistant variants (47). In some patients that did not respond to a
combination of TPV, pegylated IFN-, and ribavirin, no resis-
tance mutations were detected (48). In another study, no SOF
resistance mutations were observed after virological relapse of
HCV genotype 2 in patients subjected to SOF-based combination
therapies (49).
If a fitness-related mechanism of decreased HCV sensitivity
operated in vivo, it would mean that some treatment failures are
expected, independent of specific resistance mutations. The fit-
ness cost of resistance mutations and fitness rescue due to com-
pensatory mutations are two well-established mechanisms by
which fitness can impact the development of antiviral resistance.
The results presented here introduce new roles of fitness in con-
nection with the management of HCV infections: a direct influ-
ence on multidrug resistance and the enhanced probability that
high fitness, by virtue of its associated capacity to explore sequence
space, can promote selection of drug resistance mutations or mu-
tations that facilitate the selection of bona fide resistance muta-
tions. It should be noted that current standard methodologies to
assess the influence of specific mutations identified in break-
FIG 4 Infectious progeny production of biological clones of hepatitis C virus passaged in the absence or presence of sofosbuvir. Biological clones and their
parental populations are indicated in the upper boxes, and the absence or presence of sofosbuvir (SOF) is indicated at left. For the first passage, 4 105 Huh-7.5
reporter cells were infected with 1.2  104 TCID50 of the corresponding clone, to give a multiplicity of infection (MOI) of 0.03 TCID50/cell. For successive
infections, 4 105 Huh-7.5 reporter cells were infected with the virus contained in 500 	l of the cell culture supernatant from the previous infection, yielding a
range of MOIs of 1.25 105 to 7.9 TCID50/cell. Infections were allowed to proceed for 72 h. The abscissa axes indicate the limits of detection of virus titers.
Procedures to obtain the biological clones and infection conditions are described in Materials and Methods.
Gallego et al.
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through viruses during treatment in HCV drug resistance consist
of introducing the mutations in either infectious HCV clones or
subgenomic replicons andmeasuring their resistance levels in cell
culture. Such methods will not uncover possible fitness effects on
resistance since fitness is dependent on the sequence and popula-
tion context of the infectious virus as it replicates in the natural
liver environment (reviewed in reference 3). A major issue raised
by our study is that bona fide SOF-resistant variants may not be
selected or even selectable under current anti-HCV regimens.
However, differences in the treatment regimen and the duration
necessary to achieve an SVR may be due to fitness differences in
the starting viral population. This may underpin the decreased
SVR efficacy associated with SOF for HCV genotype 3, with SOF
requiring longer treatment durations or combination with addi-
tional DAAs.
Repeating an issue already raised during early days of the AIDS
epidemic, the value of resistance testing is being debated for guid-
ing HCV treatment decisions (50). As a general note, molecular
information has always been beneficial to improving personalized
antiviral treatments (reviewed in reference 3) unless pan-
genomic, fully effective new combination treatments become
available. The present study on fitness-dependent SOF resistance
provides an additional incentive for resistance testing in patients:
the possibility that treatment failure may occur in the absence of
selection of mutants with specific resistance mutations. This in-
formation should contribute to a better understanding of the in-
fluence exerted by quasispecies dynamics in vivo and of treatment
outcomes. Finally, the observations with HCV beg the question of
possible fitness-dependent effects of inhibitor sensitivity in other
viruses.
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